Investor Relations

Board of Directors

Blanchard
Cheryl Blanchard, Ph.D. joined the Board of Directors of Anika Therapeutics in August 2018. On April 26, 2020, Dr. Blanchard was appointed President and Chief Executive Officer of Anika Therapeutics, after serving as interim Chief Executive Officer since February 2020. Prior to her work as an executive officer with Anika, she served as the President and Chief Executive Officer of Microchips Biotech, Inc., a venture-backed biotechnology company developing regenerative medicine and drug delivery products, from 2014 until its sale to Daré Bioscience, Inc. in November 2019. Since 2012, Dr. Blanchard has also been a Principal at Blanchard Consulting, LLC which provides scientific, regulatory, and business strategy consulting services to medical device companies and private equity clients. From 2000 to 2012, she served in various officer positions of Zimmer, Inc. (now Zimmer Biomet), a medical device company focused on musculoskeletal products, including as the Senior Vice President, Chief Scientific Officer, and general manager of Zimmer Biologics. She was also a member of Zimmer’s executive committee and founded, built and led Zimmer’s Joint Preservation/Regenerative Medicine business. Prior to joining Zimmer, Dr. Blanchard built and led the medical device practice at Southwest Research Institute. Dr. Blanchard received her M.S. and Ph.D. in Materials Science and Engineering at the University of Texas at Austin and received her B.S. in Ceramic Engineering at Alfred University. Dr. Blanchard’s strong scientific background in biologics and regenerative medicine and her extensive experience in management, research and product development, business development, and regulatory affairs at multiple companies in the life science industry, will position Anika for success and help continue its evolution into a leader in joint preservation and restoration. Until her appointment as interim Chief Executive Officer, Dr. Blanchard served as a member of Anika’s Compensation Committee and Governance and Nominating Committee.
Dr. Bower

Dr. Bower joined the Board of Directors of Anika Therapeutics in February 1993. Dr. Bower served as Chair of the Board from March 9, 2018 to September 3, 2020, and he previously served as lead director from April 2005 through March 9, 2018. Since July 2014, he has been the Donald Kirk David Professor Emeritus at Harvard Business School. From 2008 through 2014, he was the Baker Foundation Professor of Business Administration at Harvard Business School, and prior to 2008, he was the Donald Kirk David Professor of Business Administration. Throughout his tenure, Dr. Bower also served in many administrative roles at Harvard Business School, including as Senior Associate Dean. Dr. Bower also serves as a director of Loews Corporation and the New America High Income Fund, Inc. During the past five years, Dr. Bower also served as a director of Brown Shoe Company, Inc. and Sonesta International Hotels Corporation. He holds an A.B., as well an M.B.A. and a D.B.A. from Harvard University. Dr. Bower brings to the Board more than four decades of experience in business strategy, corporate governance, leadership and management, during which time he has written books about and taught these subjects at the Harvard Business School. Additionally, he has consulted with numerous organizations on matters related to strategy, organizational development and succession planning. As a result, he is well suited for his role as Chair of the Compensation Committee.

Jack Image

John (“Jack”) B. Henneman, III joined the Board of Directors of Anika Therapeutics in September 2020. Mr. Henneman has more than 25 years of combined financial and operational management experience in the life sciences industry. Mr. Henneman served as Executive Vice President and Chief Financial Officer of NewLink Genetics Corporation from October 2014 to July 2018, and as its Chief Administrative Officer from July 2018 to November 2018. Prior to joining NewLink Genetics, he served lntegra LifeSciences in various capacities between 1998 and 2014. Before becoming lntegra's Chief Financial Officer in 2007, Mr. Henneman served lntegra as General Counsel and Chief Administrative Officer, responsible at various times for lntegra's business development, regulatory affairs, quality systems, clinical affairs, human resources, information systems and legal affairs and the management of lntegra's surgical instruments business. Mr. Henneman serves on the boards of directors of SeaSpine Holdings Corporation, a publicly-held medical technology company, R1 RCM, Inc., a public company providing technology-enabled revenue cycle management services to healthcare providers, Aprea Therapeutics Inc., a publicly held biotechnology company, and Alafair Biosciences, Inc., a privately-held medical device company. Mr. Henneman is also senior advisor to Prettybrook Partners, a private equity firm and a consultant to SparkMed Advisors LLC, which provides consulting and other services to start-up medical device and biotechnology companies. Mr. Henneman received an A.B. in politics from Princeton University and a J.D. from the University of Michigan Law School. Mr. Henneman serves as a member of Anika’s Compensation Committee and Governance and Nominating Committee.

Mr. Land

Mr. Land joined the Board of Directors of Anika Therapeutics in January 2006. Previously, Mr. Land served as chairman of the board of directors of BioAmber, Inc., a publicly traded company developing chemicals from renewable feedstocks, and in 2017 also served as the interim Chief Financial Officer of BioAmber, Inc. for approximately three months. From 2008 through 2010, Mr. Land served as the Senior Vice President and Chief Financial Officer of Clarient, Inc., an advanced molecular diagnostics company. From June 2007 to June 2008, he was the Senior Vice President and Chief Financial Officer of Safeguard Scientifics, Inc., a venture capital firm. Prior to Safeguard Scientifics, Inc., Mr. Land held executive management and Chief Financial Officer positions at Medcenter Solutions, Inc., a pharmaceutical marketing company where he was also a board member, and Orchid Cellmark, a provider of DNAtesting services. Mr. Land previously served as Senior Vice President and Chief Financial Officer for Genencor International, Inc., a biotechnology company focusing on bioproducts and healthcare, from 1997 until its acquisition in April 2005. From 1991 to 1996, he served as Senior Vice President and Chief Financial Officer for West Pharmaceutical Services, Inc. Previously, Mr. Land was with Campbell Soup Company, Inc. where for nine years he held increasingly senior financial positions and also served as General Manager of a frozen food division. Prior to joining Campbell Soup, he was with Coopers and Lybrand for nine years. Mr. Land is a retired Certified Public Accountant and has a B.S. degree in accounting and finance from Temple University. Mr. Land's qualifications for membership on the Board include his extensive prior experience as chief financial officer at multiple companies, including several in the life science industry. He serves as the Chair and designated financial expert on the Audit Committee and as a member of the Governance and Nominating Committee.

Financial Expert
Larsen

Dr. Larsen joined the Board of Directors of Anika Therapeutics in February 2015. He is currently Chairman, President, and Chief Executive Officer of Aquinnah Pharmaceuticals, Inc., a pharmaceutical company focused on the development of treatments for ALS, Alzheimer’s, and other neurodegenerative diseases, which he co-founded in February 2014. He is also a co-founder and Chairman of the board of directors of 180 Therapeutics L.P., a clinical stage musculoskeletal drug development company focusing on treating fibrosis, which he co-founded in 2013. He previously served as Chief Scientific Officer and Executive Vice President of Research and Development at SpringLeaf Therapeutics, Inc., a producer of combination drug delivery devices, from 2010 through 2013 and as Chief Operating Officer and Executive Vice President of Research and Development, and as a member of the board of directors, at Hydra Biosciences, Inc., a biopharmaceutical company, from 2003 through 2010. During his prior employment at Wyeth (now Pfizer)/Genetics Institute, Dr. Larsen served in various drug discovery and development leadership positions, including Vice President Musculoskeletal Sciences where he directed Wyeth’s second-largest therapeutic area with responsibility for Enbrel, an anti-TNF therapeutic with multi-billion dollar annual sales used to treat rheumatoid arthritis and other diseases. Dr. Larsen received his Ph.D. in Biochemistry from Stony Brook University and a PMD from Harvard University Business School. Dr. Larsen’s qualifications for membership on the Board include his strong scientific background in pharmaceuticals, biotech, orthopedics and regenerative medicine, and his extensive experience in management, product development and business development at multiple companies in the life science industry, all of which provide the Board with innovative product and commercial development perspectives and insights. He serves as a member of the Compensation Committee and a member of the Governance and Nominating Committee.

Steve

Stephen O. Richard joined the Board of Directors of Anika Therapeutics in September 2020. Mr. Richard currently serves as Chief Risk Officer and Chief Audit Executive at Becton, Dickinson and Company (BD). He joined BD in February 2016 and is responsible for the oversight of Enterprise Risk Management, Internal Audit, Information Security (enterprise), Product Security (connected devices), Corporate Security and Aviation, helping to align practices for each of these areas with best-in-class organizations and deliver value through continued focus on risk, governance and effective partnership with the business. Prior to joining BD, Mr. Richard held positions of increasing responsibility in Finance, Operations and Business Development with the National Basketball Association (NBA) over the course of an 18-year career. His NBA tenure also included three years based in Beijing, China, where he served as Chief Financial Officer and interim Chief Executive Officer. Prior to the NBA, he held leadership positions with Citibank, AT&T and Deloitte. Mr. Richard holds an MBA in Finance from Columbia Business School and a BS in Accounting from Northeastern University. He is a licensed Certified Public Accountant in the State of New Jersey and current Chairman of the Committee on Governance, Risk and Compliance of Financial Executives International. He also serves on the Advisory Board to the Center for Excellence in ERM at St. John's University. Mr. Richard is also a member of the Executive Leadership Council and has served two past three-year terms on the board of the New Jersey Society of CPAs. Finally, he is a life member of Kappa Alpha Psi Fraternity, Inc. Mr. Richard serves as a member of the Audit Committee.

Thompson

Mr. Thompson joined the Board of Directors of Anika Therapeutics in January 2011. He is a Partner with HealthEdge Investment Partners, LLC or HealthEdge, a Tampa, Florida based private equity firm that provides strategic capital exclusively in the healthcare industry. Mr. Thompson previously served as President, CEO, and Chairman of Enaltus, a HealthEdge portfolio company specializing in unique skincare solutions. Mr. Thompson currently serves as a director for various HealthEdge affiliated companies including Lifesync Corporation, MNG Laboratories, Formulated Solutions, LLC, The Columbus Organization, LLC, and Data Dimensions, LLC. Mr. Thompson also serves as a non-executive director for Sinclair Pharma, plc, a publicly traded, London-based, international aesthetic dermatology company. Prior to joining Anika, he served as President, Chief Executive Officer and Chairman of Advanced BioTechnologies, another HealthEdge portfolio company specializing in skincare solutions. Mr. Thompson also served as a director and the Chief Operating Officer for Stiefel Laboratories, Inc., an independent pharmaceutical company specializing in dermatology. Prior to his Chief Operating Officer role, he was Senior Vice President of U.S. Business Services of Stiefel Laboratories, Inc and President of Glades Pharmaceuticals. Earlier in his career, Mr. Thompson held sales and business management positions at Bausch & Lomb Pharmaceuticals and SmithKline Beecham. Mr. Thompson holds a B.S. in general science from the University of Pittsburgh. Mr. Thompson’s qualifications for membership on the Board include his prior experience in running a pharmaceutical company and his knowledge of the medical device industry, both of which provide the Board with product and business development perspectives and insights. As a result, he is well suited for his role as Chair of the Board.

Chairman of the Board
Vogt
Ms. Vogt joined the Board of Directors of Anika Therapeutics in October 2018. Ms. Vogt previously served as President and Chief Executive Officer of Aushon Biosystems, Inc., a developer of a multiplex immunoassay platform, from 2013 until the company was acquired by Quanterix Corporation in January 2018. From 2006 to 2011, Ms. Vogt was President and Chief Executive Officer of Seracare Life Sciences, Inc., a Nasdaq-listed life sciences developer of products facilitating human diagnostics and therapeutics. From 1981 to 2005, she served in various officer positions at Millipore Corporation (now part of MillaporeSigma, the life science business of Merck KGaA), an NYSE-listed developer of biotechnology and pharmaceutical drug therapies, including as President of the Biopharmaceutical Division, Vice President and General Manager of the Laboratory Water Division, Vice President and General Manager of the Analytical Products Division, Vice President and General Manager of the Analytical Division, and Finance Manager, Division Controller. Ms. Vogt serves on the boards of directors of Sharps Compliance Corp, a publicly-held medical waste management company and Charlotte’s Web Holdings, a publicly-held producer and distributor of hemp-based cannabidiol (“CBD”) wellness products. Ms. Vogt received her M.B.A. from Boston University with a concentration in Finance and her B.A. from Brown University in Art History. Ms. Vogt’s qualifications for membership on the Board include more than thirty-five years of experience in the global life science research, pharmaceutical, biotech and clinical diagnostics industries, during which Ms. Vogt established a reputation for driving operational efficiency and productivity, successfully scaling commercial operations, enhancing profitability by streamlining, restructuring and consolidating operations, and delivering sustained revenue and cash flow growth at multiple companies. Ms. Vogt also has a deep understanding of finance and accounting as a result of holding financial-based roles during her career and serving on the audit committees of several private and public companies. Ms. Vogt serves as Chair on the Governance and Nominating Committee and as a designated financial expert member of the Audit Committee.
Financial Expert